Crossmark

Combined impact of biosynthesized selenium nanoparticles and imipenem against carbapenem-resistant Pseudomonas aeruginosa and their associated virulence factors

Crossref DOI link: https://doi.org/10.1186/s12866-025-03932-6

Published Online: 2025-04-23

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shawky, Mohamed

Kalaba, Mohamed H.

El-Sherbiny, Gamal M. https://orcid.org/0000-0003-3968-0536
Funding

Funding for this research was provided by:

Al-Azhar University
License Information

Text and Data Mining valid from 2025-04-23

Version of Record valid from 2025-04-23
More Information

Article History

Received: 12 November 2024

Accepted: 25 March 2025

First Online: 23 April 2025

Declarations

:

: We have verified that our study was conducted on human subjects and/or human data, adhering to the principles outlined in the Helsinki Declaration, and referenced the Institutional Review Board (IRB) approval. The Institutional Review Board of National Cancer Institute (NCI), Cairo University, Egypt, authorized all protocols and procedures (IRB number: IRB-00004025; approval number: CB2410-102-083-192). Each participant signed their written informed consent form before enrolling in this study.

: Each participant signed their written informed consent form before enrolling in this study.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below